Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Drug May Prevent Type 2 Diabetes

By HospiMedica staff writers
Posted on 18 Sep 2001
A preliminary study has shown that the drug rosiglitazone may prevent the development of type 2 diabetes in patients with impaired glucose tolerance (IGT). More...
The results of the study, conducted by scientists at Newcastle University (UK), were presented at the annual conference of the European Association for the Study of Diabetes, in Glasgow, Scotland.

On average, a type-2 diabetic remains undiagnosed for seven years, by which time the damage to tissues is already underway. The number of people affected grows larger every year, due in part to a concurrent rise in obesity, which is linked to the disease, and an aging population. The new drug is taken in tablet form, making it easy for patients to comply with their prescription. The researchers say that patients taking the drug are also less likely to develop the high blood pressure usually associated with type 2 diabetes, which can lead to heart disease.

"This drug presents a therapeutic alternative for those patients that cannot make the necessary lifestyle changes,” said Dr. Mark Walker, a consulting physician at Newcastle University. The results of the IGT study have provided the proof-of-concept for a much larger prospective study that will seek to establish the effectiveness of the drug in the prevention of type 2 diabetes.




Related Links:
Newcastle Univ.

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Gas Analyzer
GE SAM
New
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.